+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 65Years
All Genders
ID07686263

Phase 3 Randomized, Double-blind Study of KarXT for Relapse Prevention in Schizophrenia

Led by Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Updated on 2026-10-30

472

Participants Needed

54

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

The trial investigates the use of KarXT XanomelineTrospium Chloride for preventing relapse in adults diagnosed with schizophrenia. Participants must have had schizophrenia for at least one year with recent hospitalization and persistent symptoms, evaluated by specific psychiatric scales. This Phase 3 randomized, double-blind, placebo-controlled study aims to assess how well KarXT maintains symptom control compared to placebo. Participants are randomly assigned to receive either KarXT or a placebo with specified doses given on set days. The study monitors participants over a period of up to approximately 43 weeks after randomization to evaluate relapse prevention. All treatments and follow-ups are masked to ensure unbiased assessment. During the study, participants undergo regular evaluations including psychiatric assessments using PANSS and CGI-S scores to measure symptom severity and relapse events. Safety is monitored through tracking of adverse events and special interest symptoms. The primary outcome measures the time from randomization to the first relapse. The total participation duration spans several months, with ongoing safety and efficacy assessments throughout the study period.

CONDITIONS

Brief Title

Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

Research Team

B

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

F

First line of the email MUST contain NCT # and Site #.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here